AADI VS FONR Stock Comparison

PerformanceTechnicalsEarningsProfitVolatilitySentiment
PerformanceTechnicalsEarningsProfitVolatilitySentiment

Performance

AADI
10/100

AADI returned -64.24% in the last 12 months. Based on SPY's performance of -13.86%, its performance is below average giving it a score of 10 of 100.

FONR
10/100

FONR returned 2.31% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

Technicals

AADI
57/100

AADI receives a 57 of 100 based on 14 indicators. 7 are bullish, 5 are bearish.

FONR
86/100

FONR receives a 85 of 100 based on 14 indicators. 12 are bullish, 2 are bearish.

Earnings

AADI
10/100

AADI has missed earnings 9 times in the last 20 quarters.

FONR

"Earnings" not found for FONR

Profit

AADI
13/100

Out of the last 20 quarters, AADI has had 2 profitable quarters and has increased their profits year over year on 2 of them.

FONR
73/100

Out of the last 20 quarters, FONR has had 20 profitable quarters and has increased their profits year over year on 7 of them.

Volatility

AADI
39/100

AADI has had a lower than average amount of volatility over the last 12 months giving it a score of 39 of 100.

FONR
59/100

FONR has had a higher than average amount of volatility over the last 12 months giving it a score of 58 of 100.

Sentiment

AADI

"Sentiment" not found for AADI

FONR
75/100

FONR had a bullish sentiment score of 75.20% across Twitter and StockTwits over the last 12 months. It had an average of 3.17 posts, 0.00 comments, and 0.00 likes per day.

All score calculations are broken down here to help you make more informed investing decisions

Aadi Bioscience, Inc. Common Stock Summary

Nasdaq / AADI
Healthcare
Biotechnology
Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.

Fonar Corporation Summary

Nasdaq / FONR
Healthcare
Medical - Devices
FONAR Corporation, together with its subsidiaries, engages in the research, development, production, and marketing of magnetic resonance imaging (MRI) scanners for the detection and diagnosis of human diseases in the United States. The company operates through two segments, Medical Equipment segment, and Physician Management and Diagnostic services segment. It provides Upright MRI scanner that allows patients to be scanned in weight-bearing conditions, such as standing, sitting, bending, or lying down. The company offers non-medical management, including administrative services, billing and collection services, credentialing services, contract negotiations, compliance consulting, purchasing IT services, hiring, conducting interviews, training, supervision and management of non-medical personnel, storage of medical records, office space, equipment, repair maintenance services, accounting, assistance with compliance matters and the development and implementation of practice growth and marketing strategies. The company owns and operates 5 diagnostic imaging facilities in Florida; and manages 39 MRI scanning facilities, including 25 facilities located in New York and 14 situated in Florida. It markets its scanners to private diagnostic imaging centers and hospitals. The company was incorporated in 1978 and is based in Melville, New York.